Option chain shows key data for Unicycive Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Unicycive Therapeutics.

Unicycive Therapeutics (NASDAQ:UNCY) Stock, Option Chain

Unicycive Therapeutics

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.

The Greenbrier Company

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

FBIO

NWGL

UNCY

Greenbrier, Fortress Biotech And 3 Stocks To Watch Heading Into Monday

Penny Stocks

Small Cap

Intraday Update

Movers

AFRM

AUUD

BTTX

CCTG

FUTU

FWBI

GIII

HEAR

HGAS

HOOD

IMRX

KPLT

MDGL

MOMO

NOVA

PANL

PATH

PERF

PIXY

PRST

PUYI

RAYA

RCMT

RGLS

RMBL

SPRB

SPRO

TCON

WIMI

WOOF

Shares of  Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates.

Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

AGFY

ARAV

BABA

BETS

BILI

BREA

CLEU

CSIQ

DADA

ENSC

ESGL

ETAO

EVAX

FAZE

GPAK

GYRE

IBRX

LIFW

LOGI

MARK

MESO

NUTX

NVVE

PLUG

REVB

RVSN

SAVE

SGMT

SLDP

SRTS

VTAK

Shares of 3M Company (NYSE: MMM) fell sharply during Tuesday’s session after the company reported better-than-expected fourth-quarter EPS, but issued FY24 EPS guidance below estimates.

Why 3M Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics Inc

Needham analyst Tom Nikic initiates coverage on Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Buy rating and announces Price Target of $84.

Price Target

Initiation

Analyst Ratings

Needham Initiates Coverage On Nike with Buy Rating, Announces Price Target of $84

ZKH Group Inks Pact With With Zhejiang Tmall Technology Co. To Establish Cooperation Of GBB Platform With Zhejiang Tmall's Industrial Product Platform; Agreement Will Be Effective Until October 31

Needham analyst Tom Nikic reiterates Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) with a Hold.

Reiteration

Needham Reiterates Hold on Under Armour

Needham analyst Tom Nikic initiates coverage on On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) with a Buy rating and announces Price Target of $64.

ONON

Needham Initiates Coverage On On Holding with Buy Rating, Announces Price Target of $64

The Starship&#8216;s many engines are isolated from each other, preventing the risk of one engine failure causing failure of all as in the case of the Soviet Union&#8217;s N1 rocket, SpaceX CEO Elon Musk said on Thursday.
What Happened: &#8220;If engine failures are isolated from each other and the primary airframe, then more engines &#x2A;increases&#x2A; reliability,&#8221; Musk said in a post on social media platform X. &#8220;The problem with N-1 was that a failure of any engine caused failure of all.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">If engine failures are isolated from each other and the primary airframe, then more engines &#x2A;increases&#x2A; reliability. The problem with N-1 was that a failure of any engine caused failure of all.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1859667589817041394?ref_src=twsrc%5Etfw">November 21, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The Starship has often been compared to the Soviet N1 rocket owing to its large number of engines. Musk himself has admitted that the <a href="https://www.benzinga.com/news/23/05/32566212/elon-musk-reacts-to-comparison-of-starship-with-doomed-rocket-that-knocked-soviet-union-out-of-moon">N1 is the closest comparable rocket to Starship</a>. However, the Starship has 33 engines on its Super Heavy booster, even more than the 30 engines on the Soviet N1&#8217;s first stage.
About N1: N1 was aimed at enabling crewed travel to the moon. However, all four attempts to launch failed and the program was suspended in 1974.
The Soviets carried out a clandestine launch of the N1 on July 3, 1969, which ended up in a colossal explosion. This effectively knocked out the Soviet Union from the Moon race just days before U.S. astronauts walked on the surface of the moon.
About Starship: Starship is SpaceX&#8217;s most ambitious launch vehicle aimed at taking humans back to the Moon and Earth&#8217;s neighboring planet Mars. 
The company has conducted six test flights of the vehicle thus far but without a payload. The last flight test took place earlier this week and NASA is looking forward to taking humans back to the surface of the Moon after a gap of over 50 years with the help of a <a href="https://www.benzinga.com/24/11/42108681/spacex-shows-off-conceptual-version-of-starship-which-will-help-humans-land-back-on-moon-in-over-50-yrs">custom version of Starship</a>.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42131163/tesla-ceo-elon-musk-attempts-to-temper-down-expectations-of-30k-optimus-or-cybercab-soon">Tesla CEO Elon Musk Tries To Lower Expectations Of $30K Optimus Or Cybercab</a></li>
</ul>
Photo courtesy: SpaceX

SPACE

Tech

General

SpaceX CEO Elon Musk Explains How Starship's Engine Design Prevents Chain Failures Unlike Soviet N1 Rocket

ZKH Group Q3 Adj EPS $(0.06), Sales $324.995M; Exits Quarter With Cash & Equivalents Worth $294.2M

Qudian (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QD#NYSE">QD</a>) reported quarterly earnings of $0.10 per share. This is a 190.91 percent increase over losses of $(0.11) per share from the same period last year. The company reported $7.80 million in sales this quarter. This is a 92.26 percent increase over sales of $4.06 million the same period last year.

Qudian Q3 Adj. EPADS $0.10 Up From $(0.11) YoY, Sales $7.80M Up From $4.06M YoY

JMP Securities analyst Matthew Carletti downgrades Root (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROOT#NASDAQ">ROOT</a>) from Market Outperform to Market Perform.

Downgrades

ROOT

JMP Securities Downgrades Root to Market Perform

Texas Governor&nbsp;Greg Abbott (R-Texas) has directed state agencies to cease investments in China and divest existing ones. This decision, announced in a letter dated Nov. 21, highlights security and financial risks associated with Chinese investments, 
What Happened: Abbott&#8217;s directive argues that this aggression could elevate the financial risks tied to Chinese investments. The governor&#8217;s letter explicitly bans Texas investing entities from making new investments in China.
Moreover, Abbott has instructed these entities to divest from any current Chinese investments at the earliest feasible opportunity. 
&#8220;Texas will defend and safeguard itself and our public treasury from any potential threat, including those posed by the CCP,&#8221; the statement read.
See Also:&nbsp;<a href="https://www.benzinga.com/24/11/42103633/chinese-court-affirms-cryptocurrency-ownership-as-legal-as-bitcoin-breaks-97k?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Chinese Judge Cites &#8216;High-Pressure Crackdown&#8217; On Speculation In Judgment Declaring Crypto Ownership Legal As Bitcoin Moves Past $97K</a>
Why It Matters: The directive from Governor Abbott comes amid escalating U.S.-China tensions. Recently, the U.S. House of Representatives advanced two Republican bills aiming to reinstate the U.S. Justice Department's "China Initiative." This initiative seeks to <a href="https://www.benzinga.com/news/24/09/40831428/house-gop-advances-bills-to-reinstate-justice-departments-china-initiative-despite-white-house-disap">curb espionage activities</a> targeting U.S. intellectual property and academic institutions. The bills were part of the House Republican's &#8220;China Week,&#8221; which saw over two dozen China-related legislative measures passed.
President-elect Donald Trump has proposed to impose 60% tariff on Chinese goods. Chinese President Xi Jinping recently <a href="https://www.benzinga.com/24/11/42025284/xi-jinping-tells-joe-biden-china-is-ready-to-work-with-trump-as-tariff-threat-looms">expressed a willingness</a> to collaborate with the U.S. government, regardless of the administration in power. This statement was made during a meeting with President Joe Biden at the Asia-Pacific Economic Cooperation forum in Lima. 
Meanwhile, ETFs that allow investment into China have dropped during the past one month. As of Nov. 22nd, according to <a href="https://pro.benzinga.com">Benzinga Pro</a>, the KraneShares CSI China Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWEB#NYSE">KWEB</a>) has dropped by 5.97% while iShares China Large-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXI#NYSE">FXI</a>) fell by 5.13%. Invesco Golden Dragon China ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGJ#NASDAQ">PGJ</a>) fell by 5.41% and iShares MSCI China ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHI#NASDAQ">MCHI</a>) dropped by 5.54%.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/42111283/elon-musks-starlink-faces-new-competition-as-chinese-satellite-firm-spacesail-enters-brazilian-market?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s Starlink Faces New Competition As Chinese Satellite Firm Spacesail Enters Brazilian Market</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Wikimedia Commons

Government

Global

KWEB

MCHI

PowerShares Golden Dragon Halter USX China Portfolio

Texas Governor Mandates State Agencies To Divest From China: 'Will Defend And Safeguard Itself...From Any Potential Threat'

Needham analyst Quinn Bolton maintains Monolithic Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) with a Buy and lowers the price target from $950 to $600.

MPWR

Needham Maintains Buy on Monolithic Power Systems, Lowers Price Target to $600

Macro Economic Events

Econ #s

Economics

U.K. Services Purchasing Managers Index Preliminary For November 50.0 Vs. 52.3 Est.; 52.0 Prior

U.K. Manufacturing Purchasing Managers Index Preliminary For November 48.6 Vs. 50.1 Est.; 49.9 Prior

U.K. Composite Purchasing Managers' Index Preliminary For November 49.9 Vs. 51.8 Prior

Eurozone Services Purchasing Managers Index Preliminary For November 49.2 Vs. 51.6 Est.; 51.6 Prior

HCOB Eurozone Composite Purchasing Managers Index Preliminary For November 48.1 Vs. 50.0 Prior

Eurozone Manufacturing Purchasing Managers Index Preliminary For November 45.2 Vs. 46.0 Est.; 46.0 Prior

HC Wainwright &amp; Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRTS#NASDAQ">DRTS</a>) with a Buy and maintains $9 price target.

DRTS

HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $9 Price Target

RBC Capital analyst Deane Dray upgrades Flowserve (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLS#NYSE">FLS</a>) from Sector Perform to Outperform and announces $69 price target.

Upgrades

RBC Capital Upgrades Flowserve to Outperform, Announces $69 Price Target

EHang Holdings Limited ("EHang" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EH#NASDAQ">EH</a>), the world's leading Urban Air Mobility ("UAM") technology platform company, today announced that the Company's Board of Directors has approved a Share Repurchase Program, pursuant to which the Company may repurchase up to&nbsp;US$30&nbsp;million of its American Depositary Shares ("ADSs") or ordinary shares over the next 12 months.

Buybacks

EHang Holdings' Board Approved A Share Buyback Program Of Up To $30M ADSs Over Next 12 Months

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Xenetic Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBIO#NASDAQ">XBIO</a>) with a Neutral.

XBIO

HC Wainwright & Co. Reiterates Neutral on Xenetic Biosciences

Analyst Ed Arce from H.C. Wainwright maintained a Buy rating on Unicycive Therapeutics (UNCY – Research Report) and keeping the price target at $2....

Unicycive Therapeutics: A Buy Rating with a $2.50 Price Target Amid Clinical and Regulatory Advances

In a report released on October 10, Robert LeBoyer from Noble Financial reiterated a Buy rating on Unicycive Therapeutics (UNCY – Research Report),...

Noble Financial Reaffirms Their Buy Rating on Unicycive Therapeutics (UNCY)

Unicycive Therapeutics (UNCY) announced that multiple presentations were delivered at the American Society of Nephrology Kidney Week 2024 that high...

Unicycive presents on development progress of oxylanthanum carbonate

Unicycive Therapeutics (UNCY) announced that the U.S. Food and Drug Administration, FDA, has accepted the New Drug Application, NDA, for Oxylanthan...

Unicycive Therapeutics announces U.S. FDA acceptane for NDA for OLC

Unicycive NDA for hyperphosphatemia asset accepted by FDA

"We are pleased with the tremendous progress we have made over the last several months highlighted by the acceptance of our New Drug Application fo...

Unicycive Therapeutics reports Q3 EPS (13c), consensus (15c)

As of September 30, 2024, cash and cash equivalents totaled $32.3 million. The Company believes that it has sufficient resources to fund planned op...

Unicycive Therapeutics expects cash to fund operations into 2026

Unicycive Therapeutics GAAP EPS of -$0.05

17:31 EST Unicycive Therapeutics (UNCY) files $100M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-mo...

Unicycive Therapeutics files $100M mixed securities shelf

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Unicycive Therapeutics (UNCY – Research Report), with a price target of $2.00. Jas...

Strategic Market Position and FDA Milestone Propel Unicycive Therapeutics to 'Buy' Rating

Press Releases

Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024

Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024

Health Care

Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers

Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024

Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024

Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024

Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update

Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference

Comments

Unicycive Therapeutics

Unicycive Therapeutics (UNCY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga